MitoPharm signed an exclusive, worldwide licensing agreement with the Hong Kong University of Science and Technology for the use and commercialization of its patent-pending process for the extraction of (-) Schisandrin B and Schisandrin B.
MitoPharm reports that it thus gains the first commercial-scale process for the extraction of Schisandrin B that delivers a high degree of purity and well-defined bacterial levels. The process incorporates hybrid chromatography, which is widely used in the fine chemical and pharmaceutical industries for the recovery of high-purity products.